MS Tech Secures $1.2M R&D Grant for Early Disease Detection Biosensor Technology
TL;DR
MS Tech Ltd. secures a $1.2M R&D grant to advance biosensor technology, offering a competitive edge in early disease detection and point-of-care diagnostics.
MS Tech's innovative biosensors, integrated with IoT, enable rapid disease biomarker detection in liquid biopsies, streamlining diagnostics without the need for lab-based analysis.
MS Tech's biosensor technology enhances global healthcare by enabling early disease detection, improving patient outcomes and making healthcare more accessible and efficient.
Exploring the future of diagnostics, MS Tech's biosensors combine nanotechnology and IoT for instant disease detection, revolutionizing healthcare and environmental monitoring.
Found this article helpful?
Share it with your network and spread the knowledge!
MS Tech Ltd., a leader in the development and manufacturing of nano- and biosensors, has recently been awarded a $1.2 million R&D grant by the Israel Innovation Authority. This grant is aimed at furthering the company's groundbreaking work in the Bio-Medical Division, specifically in the development of biosensor technology for the early detection of disease biomarkers in liquid biopsies. This advancement is part of the LIQUIDBX Consortium's efforts to revolutionize early diagnostics.
The significance of this grant lies in the potential of MS Tech's biosensors to transform the landscape of medical diagnostics. Unlike traditional liquid biopsy analyses that are both time-consuming and costly, requiring laboratory-based analytical instrumentation, MS Tech's innovative biosensors promise to deliver results within minutes. This rapid processing, combined with IoT capabilities, enables immediate data-driven decisions, significantly reducing operational delays in patient care.
Doron Shalom, CEO of MS Tech, highlighted the company's commitment to innovation in biosensor technology, stating, 'We are driving the development and innovation of biosensors that will transform early diagnostics - empowering healthcare providers and patients to take control of their health with fast point-of-care diagnostics.' This vision is part of MS Tech's broader bio-convergence movement, integrating biology, life sciences, engineering, and software to advance its HF-QCM sensor technologies.
The implications of this technological advancement extend beyond medical diagnostics, offering potential applications in agriculture, food security, environmental protection, and more. The Israel Innovation Authority's recognition of MS Tech's biosensor technologies underscores their position at the forefront of scientific and technological innovation. Since its establishment in 1998, MS Tech has been dedicated to reshaping the sensors industry, and this latest grant reaffirms their pioneering role in the field.
For more information on MS Tech's innovative sensor technologies, visit https://ms-technologies.com.
Curated from 24-7 Press Release
